Compare Archer-Daniels-Midland Co (ADM) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Boston Scientific Corporation — how do they compare? Archer-Daniels-Midland Co trades at $79.53 (market cap $38.78B), while Boston Scientific Corporation trades at $51 (market cap $74.19B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| ADM | BSX | |
|---|---|---|
Market Cap | $38.78B | $74.19B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $108.14 |
52-Week Low | $56.00 | $42.63 |
Enterprise Value | $47.03B | $86.27B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $80.49, up 5.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has declined from $101.6B in 2022 to $80.3B in 2025, but net income margin improved to 2.16% in 2025. The company raised its 2026 outlook after Q2 results, citing biofuels and nutrition strength. Valuation ratios include a P/E of 21.98 and P/S of 0.48, indicating potential undervaluation relative to earnings growth prospects.
Outlook is positive with analyst consensus price target of $88.00, though execution risks and competitive pressures remain. Investment opportunity lies in continued margin expansion and biofuel demand, while risks include volatile commodity prices and debt levels. The stock offers a dividend yield supported by 379 consecutive quarterly payments.
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
